Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2418-2425

  Panico, Luigi ^a   Ronconi, Fioravante ^a,b   Lepore, Marianna ^a   Tenneriello, Valentina ^a   Cantore, Nicola ^a   Dell'Angelo, Antonietta Carmela ^a   Ferbo, Umberto ^a   Ferrara, Felicetto ^b  

^a SG Moscati Hospital   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Classical Hodgkin lymphoma; Immunohistochemistry; Macrophages; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CD68 ANTIGEN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CHILD; CLASSICAL HODGKIN LYMPHOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHILD; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; YOUNG ADULT;

EID: 84879853725     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.778405     Document Type: Article

References (37)

1. Mani H, Jaffe ES. Hodgkin lymphoma: An update on its biology with newer insights into classification. din Lymphoma Myeloma 2009;9:206-216.
2. Ganellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin?s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
3. Hasenclever D, Diehl VA prognostic score for advanced Hodgkin?s disease. N Engl J Med 1998;339:1506-1514.
4. Tubiana M, Henry-Amar H, Garde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages 1 and 11 in Hodgkin?s disease. The EORTG lymphoma group controlled clinical trials: 1964-1987. Blood 1989;73:47-56.
5. sup SJ, Alemany GA, Pohlman B, et al. Expression of bcl-2 in classic Hodgkin?s lymphoma: An independent predictor of poor outcome. J Glin Oncol 2005;23:3773-3779.
6. Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al. Topoisomerase 11ct expression as an independent prognostic factor in Hodgkin?s lymphoma. Glin dancer Res 2008;14:1759-1766.
7. Diepstra A, Van Imhoft GW, Karim-Kos HE, et al. HLA class 11 expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin?s lymphoma. J Glin Oncol 2007;25:3 10 1-3 108
8. Hsi ED, sup SJ, Alemany C, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol 2006;125:776-782.
9. Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classic Hodgkin?s disease. Oncogene 2002;21:3095-3102.
10. Sanchez-Aguilera A, Montalban C, de La Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662-668.
11. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classic Hodgkin lymphoma tissue uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765-2775.
12. Alvaro I, Lejeune M, Salvado MI, et al. Outcome in Hodgkin?s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-1473.
13. Kelley TW, Pohlman B, Elson P, et al. The ratio of FOXP3 + regulatory 1 cells to Granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007:128:958-965.
14. Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin?s lymphoma. Br J Haematol 2002;119:122-124.
15. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224-2234.
16. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin?s lymphoma. N Engl J Med 2010:362: 875-885.
17. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301-308.
18. Kamper P, Bendix K, Hamilton-Dutoit 5, et al. Thmor-1nfiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin?s lymphoma. Haematologica 2011;96:269-276.
19. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011;52: 1913-1919.
20. Zaki MAA, Wada N, Ikeda J, et al. Prognostic implication of types of tumor associated macrophages in Hodgkin lymphoma. Virchows Arch 2011;459:361-366.
21. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Fur J Haematol 201 1;88:292-305.
22. Deau B, Bachy E, Ribrag V, et al. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma 2013;54:41-45.
23. Tan KL, Scott DW, Hong F, et al. Tumor associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: A correlative study form the E2496 Intergroup trial. Blood 2012;120:3280-3287.
24. Azambuja D, Natkunam Y, Biasoli I, et al. Lack of association of tumor associated macrophages with clinical outcome in patients with classical Hodgkin?s lymphoma. Ann Oncol 2012;23:736-742.
25. Agostinelli C, Gallamini A, Rigacci L, et al. The prognostic value of biologic markers in classical Hodgkin lymphoma (CHL) patients. Ann Oncol 2012;22(Suppl. 4): Abstract 206.
26. Harris JA, Jam 5, Ren Q, et al. CD 163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012;7:12-17.
27. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin?s lymphoma. Haematologica 2012;97:1080-1084.
28. Ruan J, Hyjek E, ICermani P, et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin?s lymphoma. Clin Cancer Res 2006;12:5622-5631.
29. Gratzinger D, Zhao 5, Marinelli RJ, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large cell lymphoma subtypes. Am J Pathol 2007;170: 1362-1369.
30. Ruan L Hajjar K, Raf11 5, et al. Angiogenesis and antiangiogenic therapy in non-Hodgkin?s lymphoma. Ann Oncol 2009;20:413-424.
31. Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin?s lymphoma: A morphometric approach in 286 patients with prognostic implications. Leukemia 2005;19:894-900.
32. Glimelius I, Edstrom A, Fischer M, et al. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 2005; 19:2360-2362.
33. Grimshaw MMJ, Balkwill FR. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation -A potential mechanism. Eur J Immunol 2001;31:480-489.
34. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-612.
35. Ree HJ, Marshall ETC. Macrophage-histiocytes in Hodgkin?s disease. The relation of peanut-agglutinin-binding macrophagehistiocytes to clinicopathologic presentation and course of disease. Cancer 1985;56:333-338.
36. MantovaniA, Schioppa I, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006:25:315-322.
37. Igreja C, Courinha M, Cachaço AS, et al. Characterization and clinical relevance of circulating and biopsy derived endothelial progenitor cells in lymphoma patients. Haematologica 2009;92: 469-477.